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Abstract 
Background: Capecitabine and irinotecan combination therapy (XELIRI) has been examined at various dose levels 
to treat metastatic colorectal cancer (mCRC). Recently, in the Association of Medical Oncology of the German Cancer 
Society (AIO) 0604 trial, tri‑weekly XELIRI plus bevacizumab, with reduced doses of irinotecan (200 mg/m2 on day 1) 
and capecitabine (1600 mg/m2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and efficacy 
which were comparable to those of capecitabine and oxaliplatin (XELOX) plus bevacizumab. The doses of capecit‑
abine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab (BIX) as 
second‑line chemotherapy was well tolerated and had promising efficacy in Japanese patients.
Methods: The Asian XELIRI ProjecT (AXEPT) is an East Asian collaborative, open‑labelled, randomized, phase III clinical 
trial which was designed to demonstrate the non‑inferiority of XELIRI with or without bevacizumab versus standard 
FOLFIRI (5‑fluorouracil, leucovorin, and irinotecan combination) with or without bevacizumab as second‑line chemo‑
therapy for patients with mCRC. Patients with 20 years of age or older, histologically confirmed mCRC, Eastern Coop‑
erative Oncology Group performance status 0–2, adequate organ function, and disease progression or intolerance 
of the first‑line regimen will be eligible. Patients will be randomized (1:1) to receive standard FOLFIRI with or with‑
out bevacizumab (5 mg/kg on day 1), repeated every 2 weeks (FOLIRI arm) or XELIRI with or without bevacizumab 
(7.5 mg/kg on day 1), repeated every 3 weeks (XELIRI arm). A total of 464 events were estimated as necessary to show 
non‑inferiority with a power of 80% at a one‑sided α of 0.025, requiring a target sample size of 600 patients. The 95% 
confidence interval (CI) upper limit of the hazard ratio was pre‑specified as less than 1.3.
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Background
Life-prolonging systemic therapies, e.g., chemothera-
pies with or without molecular targeted agents such as 
anti-vascular endothelial growth factor (VEGF) or anti-
epidermal growth factor receptor (EGFR) agents, are 
important for unresectable metastatic colorectal cancer 
(mCRC). The National Comprehensive Cancer Network 
(NCCN) guidelines [1], the European Society for Medi-
cal Oncology (ESMO) clinical practice guidelines [2], and 
the Japanese Society for Cancer of the Colon and Rec-
tum (JSCCR) guidelines [3] recommend four basic cyto-
toxic chemotherapy regimens as options to patients with 
mCRC who are able to tolerate intensive therapy.
Recently, head-to-head randomized phase III stud-
ies comparing bevacizumab and cetuximab (e.g., FIRE-3 
and CALGB80405) did not show a consistent substantial 
difference in response rate, overall survival (OS), or pro-
gression-free survival (PFS) [4–6]. A randomized phase 
III study (STRATEGIC-1) that was designed to deter-
mine the best sequence of systemic therapy is now in 
progress [7].
Combination chemotherapy using oral drugs is con-
venient, freeing patients from chemoports or infusion 
pumps. However, compelling evidence for the safety and 
efficacy of such regimens is required.
In a phase III BICC-C study conducted mainly in the 
United States, tri-weekly XELIRI regimen (also named 
CapeIRI regimen: intravenous infusion of irinotecan 
250 mg/m2 on day 1 and oral administration of capecit-
abine 2000  mg/m2 per day on days 1–15) was com-
pared with FOLFIRI regimen (intravenous infusion of 
irinotecan 180  mg/m2, leucovorin [LV] 400  mg/m2, and 
5-fluorouracil [5-FU] 400 mg/m2 on day 1 followed by a 
46-hour infusion of 5-FU 2400  mg/m2, repeated every 
2 weeks) and modified IFL regimen (intravenous infusion 
of irinotecan 125 mg/m2 on day 1, LV 20 mg/m2 and 5-FU 
500 mg/m2 on days 1 and 8, repeated every 3 weeks) [8]. 
Grade 3/4 adverse events mainly consisting of gastroin-
testinal toxicities occurred more frequently in patients 
treated with CapeIRI than in those treated with FOLFIRI 
(nausea, 18.4% vs. 8.8%; diarrhea, 47.5% vs. 13.9%; dehy-
dration, 19.1% vs. 5.8%); median PFS was significantly 
shorter for patients treated with CapeIRI than for those 
treated with FOLFIRI (5.8 vs. 7.6  months, P  =  0.015) 
due to early discontinuation of CapeIRI regimen. The 
authors suggested that the large number of patients with 
early treatment discontinuations for adverse events in the 
CapeIRI group may because of regional and ethnic differ-
ences in the metabolism of 5-FU and capecitabine, espe-
cially between patients in the United States and East Asia 
[8, 9]. Subsequently, a modified XELIRI regimen, with 
reduced doses of irinotecan and capecitabine, was stud-
ied in combination with bevacizumab, mainly in studies 
comparing FOLFIRI and XELOX regimens (intravenous 
infusion of oxaliplatin 130  mg/m2 on day 1 plus oral 
administration of capecitabine 2000  mg/m2 per day on 
days 1–15) [10–13].
Recently, in the AIO 0604 trial, tri-weekly XELIRI plus 
bevacizumab, with reduced doses of irinotecan (200 mg/
m2 on day 1) and capecitabine (1600 mg/m2 per day on 
days 1–14), was compared with XELOX plus bevaci-
zumab [13]. Common grade 3/4 adverse events included 
diarrhea (16% for the XELIRI arm and 22% for the 
XELOX arm), nausea (3% for each arm), and fatigue (3% 
for each arm). The median PFS was 12.1 vs. 10.4 months 
[13]. This randomized phase II trial showed that XELIRI 
plus bevacizumab had equivalent efficacy to XELOX plus 
bevacizumab, even though the XELIRI-based regimen 
was designed primarily to reduce adverse events.
In Japan, a completed phase I/II study evaluated the 
efficacy of the XELIRI regimen using the same dose in the 
AIO 0604 trial for patients with mCRC who had previ-
ously been treated with oxaliplatin and bevacizumab (the 
BIX study) [14]. The most common grade 3/4 adverse 
events were neutropenia (8.8%), nausea (5.9%), diarrhea 
(5.9%), and fatigue (2.9%). The efficacy analysis demon-
strated an overall response rate of 17.6% and median PFS 
of 8.3  months. These results suggest that XELIRI plus 
bevacizumab would be safe and effective for East Asian 
patients with mCRC. Considering that there are regional 
differences between the United States and East Asian 
patients with respect to the metabolism of capecitabine 
and 5-FU and that gastrointestinal toxicities may be more 
tolerable for East Asian patients, XELIRI plus bevaci-
zumab may be more appropriate for Asian patients [9]. 
Therefore, XELIRI with or without bevacizumab was 
assigned to the study therapy group in the AXEPT trial.
Homozygosity or double heterozygosity for UDP-glu-
curonosyl transferase 1A1 (UGT1A1) polymorphisms 
(UGT1A1*28 and UGT1A1*6) may relate to increased 
Conclusion: The Asian XELIRI ProjecT is a multinational phase III trial being conducted to provide evidence for XELIRI 
with or without bevacizumab as a second‑line treatment option of mCRC.
Trial registration ClinicalTrials.gov NCT01996306. UMIN000012263
Keywords: Metastatic colorectal cancer, Randomized phase III clinical trial, XELIRI, Bevacizumab, Second‑line therapy
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serious adverse events, such as neutropenia and diarrhea, 
in patients treated with an irinotecan-based regimen. A 
reduced dose of irinotecan is therefore needed in patients 
with these polymorphisms [15–19].
Methods
Objectives
The primary objective is to demonstrate the non-inferi-
ority in terms of OS for XELIRI with or without bevaci-
zumab versus FOLFIRI with or without bevacizumab as 
second-line therapy for patients with mCRC.
The secondary objectives are to evaluate the PFS, time 
to treatment failure (TTF), overall response rate (ORR), 
disease control rate (DCR), relative dose intensity (RDI), 
safety, and association between UGT1A1 polymorphisms 
and the occurrence rates of adverse events. Exploratory 
subgroup analysis is planned to investigate factors which 
are thought to influence prognosis, including country, 
Kirsten rat sarcoma viral oncogene homolog (KRAS) gen-
otype, and UGT1A1 genotype.
XELIRI improves treatment convenience by elimi-
nating continuous intravenous infusion and permitting 
fewer hospital visits (every 3 weeks). Therefore, demon-
stration of the non-inferiority of XELIRI with or without 
bevacizumab versus FOLFIRI with or without bevaci-
zumab will provide new evidence for this novel treatment 
option as second-line therapy for mCRC.
Trial design
AXEPT is an East Asian collaborative, open-labelled, 
randomized, non-inferiority, phase III clinical trial com-
paring the efficacy and safety of XELIRI with or without 
bevacizumab versus FOLFIRI with or without bevaci-
zumab in patients with mCRC.
After written informed consent has been obtained, 
eligible patients will be randomized (1:1) to either the 
XELIRI arm or the FOLFIRI arm using minimization 
methods by the Swedish central electronic case-report 
form system (eCRF: VIEDOC®, PCG Solutions Co. Ltd., 
Uppsala, Sweden). Stratification factors will include 
(1) country (Japan vs. South Korea vs. China), (2) East-
ern Cooperative Oncology Group performance status 
(ECOG PS) (0–1 vs. 2), (3) number of metastatic sites (1 
vs. >1), (4) prior oxaliplatin treatment (yes vs. no), and (5) 
concomitant bevacizumab treatment (with vs. without).
The study will be conducted in three countries, Japan, 
South Korea, and China (Fig. 1). The steering committee 
consists of a principal investigator from each country and 
a biostatistician. A total of 600 patients will be enrolled 
from 73 Japanese hospitals, 8 South Korean hospitals, 
and 17 Chinese hospitals.
Study population
Patients who meet all of the below inclusion criteria and 
none of the exclusion criteria will be eligible for enroll-
ment in this study.
Inclusion criteria
1. Histologically confirmed unresectable colorectal ade-
nocarcinoma
2. Age ≥20 years
3. ECOG PS 0–2
4. Signed and dated written informed consent
5. Life expectancy >90 days
6. Withdrawal from first-line chemotherapy (regardless 
of the combination with or without molecular tar-
geted agents) for mCRC due to intolerable toxicity or 
disease progression, or relapse within 180 days after 
the last dose of adjuvant chemotherapy
7. Adequate organ functions according to the following 
laboratory values which are obtained within 14 days 
before enrollment
Patients with metastatic colorectal cancer undergoing a 




(1) Region (Japan vs. South Korea vs. China)
(2) ECOG PS (0-1 vs. 2)
(3) Number of metastatic sites/organs (1 vs. >1)
(4) Prior oxaliplatin treatment (no vs. yes)










Repeat every 2 weeks
Trial design
Fig. 1 Study design of the Asian XELIRI ProjecT (AXEPT). *All patients 
from South Korea and Japan will receive concomitant bevacizumab 
treatment; whereas those from China will be treated either with 
or without concomitant bevacizumab treatment. ECOG PS Eastern 
Cooperative Oncology Group performance status. The FOLFIRI arm: 
intravenous infusion of irinotecan 180 mg/m2, leucovorin 400 mg/m2, 
and 5‑fluorouracil 400 mg/m2 on day 1 followed by a 46‑h infusion 
of 5‑fluorouracil 2400 mg/m2, repeated every 2 weeks. The XELIRI 
arm: intravenous infusion of irinotecan 200 mg/m2 on day 1 and oral 
administration of capecitabine 1600 mg/m2 per day on days 1–14, 
repeated every 3 weeks
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• Neutrophil count ≥1500/mm3
•  Platelet count ≥100 × 103/mm3
•  Hemoglobin ≥9.0 g/dL
•  Total bilirubin ≤1.5 mg/dL
•  Aspartate aminotransferase (AST)  ≤100  IU/L 
(100 U/L) (≤200 IU/L [200 U/L] if liver metasta-
ses are present)
•  Alanine transaminase (ALT)  ≤100  IU/L 
(100 U/L) (≤ 200 IU/L [200 U/L] if liver metas-
tases are present)
•  Serum creatinine ≤1.5 mg/dL
Exclusion criteria
 1. History of other malignancies with a disease-free 
interval <5 years
 2. Massive pleural effusion or ascites requiring inter-
vention
 3. Radiological evidence of brain tumor or brain metas-
tases
 4. Active infection, including hepatitis
 5. Any of the following concurrent diseases:
• Gastrointestinal bleeding or gastrointestinal 
obstruction (including paralytic ileus)
•  Symptomatic heart disease (including unstable 
angina, myocardial infarction, and heart failure)
•  Interstitial pneumonia or pulmonary fibrosis
•  Uncontrolled diabetes mellitus
•  Uncontrolled diarrhea (that interferes with daily 
activities despite adequate therapy)
 6. Any of the following in the medical history:
• Myocardial infarction (history of one episode 
within 1 year before enrollment or two or more 
lifetime episodes)
•  Serious hypersensitivity to any of the study drugs
•  History of adverse reaction to fluoropyrimidines 
suggesting dihydropyrimidine dehydrogenase 
deficiency
 7. Previous treatment with irinotecan
 8. Current treatment with atazanavir sulfate
 9. Previous treatment with tegafur, gimeracil, and 
oteracil potassium within 7 days before enrollment
 10. Pregnant or lactating women, and men or women 
unwilling to use contraception
 11. Requirement for continuous treatment with steroids
 12. Psychiatric disability that would preclude study com-
pliance
 13. Otherwise determined by the investigator to be 
unsuitable for participation in the study
Additional exclusion criteria for those receiving 
bevacizumab:
1. Concurrent gastrointestinal perforation or history 
of gastrointestinal perforation within 1  year before 
enrollment
2. History of pulmonary hemorrhage/hemopty-
sis ≥grade 2 (defined as at least 2.5 mL of bright red 
blood) within 1 month before enrollment
3. History of laparotomy, thoracotomy, or intestinal 
resection within 28 days before enrollment
4. Incomplete wound healing (except suture wounds 
from implantation of a central venous port), gastroin-
testinal ulcer, or traumatic fracture
5. Current or recent (within 1 year) thromboembolism 
or cerebrovascular disease
6. Currently receiving or requiring anticoagulation 
therapy (>325 mg/day of aspirin)
7. Bleeding diathesis, coagulopathy, or coagulation 
factor abnormality (international normalized ratio 
[INR] ≥1.5 within 14 days before enrollment)
8. Uncontrolled hypertension
9. Urine protein by dipstick > +2
Study treatment
Patients will be randomly assigned to receive one of the 
following treatments:
The FOLFIRI arm: intravenous infusion of irinotecan 
180 mg/m2, l-LV 200 mg/m2 (or d,l-LV 400 mg/m2), beva-
cizumab 5 mg/kg, and 5-FU 400 mg/m2 on day 1 followed 
by a 46-hour continuous infusion of 5-FU 2400  mg/m2, 
repeated every 2  weeks until disease progression, unac-
ceptable toxicity, or patient withdrawal.
The XELIRI arm: intravenous infusion of irinotecan 
200  mg/m2 and bevacizumab 7.5  mg/kg on day 1, and 
oral administration of capecitabine 1600 mg/m2 on days 
1–14, repeated every 3  weeks until disease progression, 
unacceptable toxicity, or patient withdrawal.
In both arms, the dose for irinotecan will be started at 
150  mg/m2 in patients identified to be homozygous for 
UGT1A1*6 or UGT1A1*28 or double heterozygous for 
UGT1A1*6 and UGT1A1*28 at baseline screening [20].
All adverse events will be assessed according to the 
National Cancer Institute Common Toxicity Criteria 
Adverse Event v4.0 (NCI CTCAE v4.0) [21].
In both arms, the protocol treatment will be started 
upon the investigator’s decision based on lab val-
ues within the inclusion criteria at the start of a treat-
ment cycle. The next cycle should not be administered 
unless the neutrophil count  ≥  1500/mm3, platelet 
count  ≥  75,000/mm3, serum total bilirubin  ≤  1.5  mg/
dL, serum creatinine ≤ 1.5 mg/dL, hand-foot syndrome 
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grade ≤ 1, and other non-hematologic toxicities resolve 
to grade  ≤  1. In those receiving bevacizumab, treat-
ment should not be administered unless hypertension 
grade  ≤  2, proteinuria  ≤  2+, venous thromboembo-
lism grade ≤  2, and hemorrhage grade ≤  1. If the next 
cycle cannot be started within 28 days of the scheduled 
start date, the protocol treatment will be discontinued. 
If adverse events that require dose reduction occur prior 
to a cycle, dose reduction could be done twice as appro-
priate. If more than two dose reductions are required, 
treatment with that drug will be discontinued. Once a 
dose reduction has been done, the dose should not be 
increased in subsequent cycles.
Statistical considerations
The analysis set is the all-randomized population. In the 
primary analysis, the cumulative OS curve, median OS, 
and annual OS rate will be estimated with the Kaplan–
Meier method, and the confidence interval (CI) of the 
median OS will be calculated with the Brookmeyer and 
Crowley method. The point estimates of the hazard ratio 
(HRs) and their 95% CIs will be calculated with a Cox 
proportional hazard model.
Secondary endpoints will be analyzed to supplement 
the results of the primary analysis. No adjustments will 
be made for multiplicity because the analysis of second-
ary endpoints is exploratory. Intergroup comparisons 
will be performed as necessary, but P values obtained 
from statistical tests will be considered reference data 
only. Exploratory subgroup analysis for factors thought to 
influence prognosis, including country, KRAS genotype, 
and UGT1A1 genotype, will be performed.
The sample size of this study was calculated on the 
basis of two previously reported phase III studies which 
included FOLFIRI plus bevacizumab or XELIRI plus 
bevacizumab as second-line treatment of patients 
with mCRC. In the FIRIS study, the median survival 
time (MST) was 18.2  months in the FOLFIRI group 
(13.7  months in patients previously treated with oxali-
platin-based therapy) [22]. In the ML18147 study, the 
MST was 10.0 months in the group receiving irinotecan-
based chemotherapy, such as FOLFIRI and XELIRI, and 
12.0  months in the group receiving irinotecan-based 
chemotherapy plus bevacizumab [23]. The add-on effect 
of bevacizumab has also been confirmed by phase II 
studies on Japanese [24], South Korean [25, 26], and 
Chinese patients [27, 28] and by a retrospective analy-
sis report [29]. In addition, the results of the ML18147 
trial [23] and E3200 trial [30] indicate that the add-on 
effect of bevacizumab in second-line treatment is similar 
between patients with and without previous treatment of 
concomitant bevacizumab. Based on the above consid-
erations, we assumed to observe an MST of 11.0 months 
for patients treated with FOLFIRI and 13.0  months for 
patients treated with FOLFIRI plus bevacizumab. Due 
to differences in regional medical environment, all South 
Korean and Japanese patients will receive concomitant 
bevacizumab treatment, whereas patients enrolled from 
China are expected to include those who do not receive 
concomitant bevacizumab treatment. On the basis of 
the estimated proportion of patients receiving treatment 
with or without bevacizumab and the estimated MST for 
each of these groups, the MST of patients in the FOL-
FIRI arm was assumed to be 12.6  months. Calculation 
of the required sample size under these conditions with 
the following assumptions revealed that an estimated 464 
events would be needed to achieve at least 80% power.
(i)   HR of treatment to control: 1.00 (MST, 
12.6  months for the FOLFIRI arm vs. 
12.6 months for the XELIRI arm)
(ii)  Upper margin of the non-inferiority hypothesis: 
HR of 1.30 (MST, 12.6 months for the FOLFIRI 
arm vs. 9.7 months for the XELIRI arm)
(iii) One-sided significance level: 0.025
(iv) Enrollment period: 24 months
(v)  Follow-up period: 18 months
An enrollment of 600 patients, including a 5% annual 
dropout rate, was therefore set in the study.
The non-inferiority upper margin of HR was set at 1.30 
(9.7 months as converted to MST) considering the vari-
ation of the 95% CI of MST with stratification by KRAS 
status or therapy with anti-EGFR antibody drugs after the 
protocol treatment. If the above non-inferiority hypoth-
esis was achieved, the hypothesis will be tested using a 
non-inferiority upper margin of HR of 1.25.
For sensitivity analysis, Cox regression analysis will 
also be performed, adding the KRAS status as a covariate 
to avoid the influence of anti-EGFR antibody treatment 
after the protocol treatment. If necessary, Cox regression 
analysis will be performed with adjusted demographic 
factors (for imbalance between the two treatment arms) 
rather than stratification factors.
Study coordination and ethical aspects
The study will be conducted according to the protocol in 
compliance with the principles of the Declaration of Hel-
sinki, International Conference of Harmonization Good 
Clinical Practice Efficacy 6 (ICH-GCP E6) [31], and the 
rules and regulations of each country.
The Epidemiological and Clinical Research Informa-
tion Network (ECRIN) is responsible for study manage-
ment (including enrollment) and monitoring of Japanese 
sites and will also assist with and oversee local study 
management in each data center. ECRIN delegates its 
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responsibility to the South Korean and Chinese local data 
centers for study preparation, contract, patient enroll-
ment within the designated study term, exchange of 
safety data, document archives, quality checks/quality 
assurance, and other local procedures which are stated in 
the ICH-GCP and local regulations.
The protocol and the informed consent form used in 
the study must be approved by the Institutional Review 
Board (IRB)/Independent Ethics Committee (IEC) at 
each study site prior to the start of study. If IRB/IEC 
approval is obtained, the site principal investigator will 
send the copy of IRB/IEC approval document to each 
data center. The original IRB/IEC approval document will 
be retained by the site principal investigator, and a copy 
will be retained at the local data center.
The study protocol was approved by the ECRIN central 
IRB on September 3, 2013 and was registered at Clini-
caltrials.gov (NCT01996306 on November 22, 2013) and 
UMIN-CTR (UMIN000012263 on November 11, 2013).
In this study, an Independent Data Monitoring Com-
mittee (IDMC) is established to determine whether this 
study is conducted appropriately. The role of the IDMC 
is to assess at intervals the progress of a clinical trial, 
the safety data, and the critical efficacy endpoints and 
to recommend the Steering Committee and study spon-
sor whether to continue, modify, or stop the trial. IDMC 
members will not be directly involved in the conduction 
or operation of the trial.
Discussion
The XELIRI regimen has already been examined at vari-
ous doses and combinations since the beginning of the 
twenty first century [8, 10–14, 25]. The XELIRI regimen 
used in the AIO 0604 trial is regarded appropriate in 
terms of efficacy and safety [13]. In addition, according to 
the ML18147 study [23], 12% of all enrolled patients were 
treated with the tri-weekly XELIRI plus bevacizumab 
regimen (AIO XELIRI regimen), and approximately 35% 
with the irinotecan-based regimen.
However, XELIRI has not been recommended by 
guidelines (neither from ESMO nor NCCN) because of 
its toxicities. For that reason, a phase II study (the BIX 
trial) was conducted to determine the tolerability of the 
AIO XELIRI regimen in Japanese patients. The results 
showed that the safety profile was acceptable and the 
efficacy was promising [14]. Thus, we planned this ran-
domized phase III trial, collaborating with investigators 
from China and South Korea.
In addition, with regard to UGT1A1 polymorphisms, it 
is necessary to evaluate the association between UGT1A1 
polymorphisms and safety or efficacy in East Asian popu-
lation and to establish clear rules of dose reduction for 
irinotecan. Thus, we will check UGT1A1 genotype at the 
baseline screening and set an initial irinotecan dose for 
patient with UGT1A1 polymorphism. The association 
between UGT1A1 genotype and safety will be further 
explored in subgroup analysis.
Demonstration of the non-inferiority of XELIRI with 
or without bevacizumab to FOLFIRI with or without 
bevacizumab in our study will provide evidence for a new 
treatment option as second-line therapy for mCRC.
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